0.773
2.52%
+0.019
Assertio Holdings Inc stock is currently priced at $0.773, with a 24-hour trading volume of 890.31K.
It has seen a +2.52% increased in the last 24 hours and a -23.47% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.762 pivot point. If it approaches the $0.79 resistance level, significant changes may occur.
Assertio Holdings Inc Stock (ASRT) Financials Data
Assertio Holdings Inc (ASRT) Revenue 2024
ASRT reported a revenue (TTM) of $169.43 million for the quarter ending September 30, 2023, a +21.71% rise year-over-year.
Assertio Holdings Inc (ASRT) Net Income 2024
ASRT net income (TTM) was -$186.00 million for the quarter ending September 30, 2023, a -824.37% decrease year-over-year.
Assertio Holdings Inc (ASRT) Cash Flow 2024
ASRT recorded a free cash flow (TTM) of $70.07 million for the quarter ending September 30, 2023, a +25.05% increase year-over-year.
Assertio Holdings Inc (ASRT) Earnings per Share 2024
ASRT earnings per share (TTM) was -$2.02 for the quarter ending September 30, 2023, a -474.07% decline year-over-year.
Assertio Holdings Inc Stock (ASRT) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Schlessinger Sam | SVP, General Counsel |
Feb 21 '24 |
Option Exercise |
0.00 |
17,151 |
0 |
109,384 |
Patel Ajay | SVP and CFO |
Feb 21 '24 |
Option Exercise |
0.00 |
17,151 |
0 |
141,760 |
Schwichtenberg Paul | SVP, CCO |
Feb 21 '24 |
Option Exercise |
0.00 |
17,151 |
0 |
112,430 |
Schlessinger Sam | SVP, General Counsel |
Feb 11 '24 |
Option Exercise |
0.00 |
18,939 |
0 |
98,785 |
Patel Ajay | SVP and CFO |
Feb 11 '24 |
Option Exercise |
0.00 |
47,348 |
0 |
140,991 |
Schwichtenberg Paul | See Remarks |
Feb 11 '24 |
Option Exercise |
0.00 |
47,348 |
0 |
111,661 |
Schlessinger Sam | SVP, General Counsel |
Oct 01 '23 |
Option Exercise |
0.00 |
19,404 |
0 |
88,442 |
Peisert Daniel A. | President & CEO |
Sep 12 '23 |
Sale |
2.97 |
31,121 |
92,432 |
324,939 |
Peisert Daniel A. | President & CEO |
Sep 11 '23 |
Sale |
3.04 |
127,281 |
386,972 |
356,060 |
Schwichtenberg Paul | SVP and CFO |
Sep 11 '23 |
Sale |
3.07 |
104,980 |
322,593 |
64,313 |
Assertio Holdings Inc Stock (ASRT) Latest News
Assertio to Present at LD Micro Invitational Conference in New York City
GlobeNewswire Inc.
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Assertio Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire Inc.
Assertio Holdings, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
GlobeNewswire Inc.
Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why
Zacks Investment Research
Assertio Holdings: Here's A Contrarian Opportunity In The Health Care Sector
Seeking Alpha
About Assertio Holdings Inc
Assertio Therapeutics, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. It has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc.; and a license agreement with Janssen Pharmaceuticals, Inc. based on its proprietary Acuform gastroretentive drug delivery technology. The company sells its products to wholesalers and retail pharmacies. The company was formerly known as Depomed Inc. and changed its name to Assertio Therapeutics, Inc. in August 2018 Assertio Therapeutics, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.
Cap:
|
Volume (24h):